Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Eli Lilly Will Bear The Cost Of A $35 Price Cap On All Copays For Its Insulins
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
You may also be interested in...
Designed as its US commercial arm following a major investment four years ago, Chinese player Nanjing King-Friend Biochemical Pharmaceutical has signed a deal allowing Meitheal Pharmaceuticals to sell three insulin biosimilars in the US.
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.
Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.